BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note published on Tuesday morning. The firm issued a sell rating on the medical technology company’s stock.

Several other brokerages also recently commented on BIOL. Maxim Group downgraded shares of BIOLASE from a strong-buy rating to a hold rating in a report on Friday, May 24th. Benchmark reaffirmed a speculative buy rating and set a $0.40 target price on shares of BIOLASE in a research note on Monday, August 12th. Finally, Ascendiant Capital Markets decreased their price target on BIOLASE from $3.50 to $2.00 and set a buy rating for the company in a research note on Tuesday, September 3rd.

BIOLASE Stock Performance

Shares of BIOLASE stock opened at $0.06 on Tuesday. The stock has a market cap of $1.84 million, a price-to-earnings ratio of 0.00 and a beta of 0.66. The stock has a 50 day moving average price of $0.06 and a 200-day moving average price of $0.12. BIOLASE has a one year low of $0.04 and a one year high of $2.10.

BIOLASE (NASDAQ:BIOL) last posted its quarterly earnings data on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%. The firm had revenue of $11.56 million for the quarter.

Institutional Investors Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC grew its stake in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.79% of the company’s stock.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.